Form 4: Imunon Director Acquires Shares

Imunon, Inc. Director James E. Dentzer reports acquisition of 11,148 shares of common stock.

Summary

• James E. Dentzer, a Director at Imunon, Inc., acquired 11,148 shares of common stock on May 22, 2026.
• The acquisition was made at a price of $2.20 per share.
• This transaction represents shares granted in lieu of cash for a portion of board fees.
• Following this transaction, Dentzer beneficially owns 14,963 shares of common stock.
• The filing also notes a 15% stock dividend paid on August 21, 2025, which adjusted previously reported share amounts.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the share acquisition is part of a standard compensation package rather than an open market purchase, indicating neither a strong positive nor negative signal.

Positives

• Director compensation partially in stock aligns management interests with shareholders.
• The acquisition of shares by a director can signal confidence in the company's future prospects.

Negatives

• The acquisition is a result of compensation, not an open market purchase, which may carry less positive sentiment.

Risks

• The filing does not explicitly detail risks, but general risks associated with biotechnology companies, such as clinical trial outcomes, regulatory approvals, and market competition, would apply to Imunon, Inc.

Future Outlook

The filing does not contain forward-looking statements or guidance. It is a report of a past transaction.

Management Comments

• Stock granted in lieu of cash for portion of board fees.
• As a result of the stock dividend, the shares of Issuer Common Stock have been adjusted accordingly versus any amounts previously reported by the Reporting Person.

Industry Context

StockSavvy.ai notes that insider stock grants as part of compensation are common in the biotechnology sector, particularly for early-stage companies where cash conservation is often a priority. This practice aims to align executive and director incentives with long-term shareholder value.

Related Party Transactions

• The acquisition of shares by Director James E. Dentzer in lieu of cash for board fees constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The alignment of director compensation with stock ownership may be viewed positively, potentially leading to decisions that benefit long-term shareholder value.
• Employees: The practice of equity compensation can extend to employees, fostering a sense of ownership and shared success.
• Management: The transaction reflects the compensation structure for directors.

Next Steps

• Continued reporting of any future changes in beneficial ownership by insiders.

Key Dates

Keywords

Imunon Inc, IMNN, Form 4, Insider Trading, Director Compensation, Common Stock, Securities Ownership